BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 27, 2026
Home » Newsletters » BioWorld

BioWorld

March 5, 2012

View Archived Issues

Congress Seeks Answers to Growing Rx Drug Abuse

WASHINGTON – With the misuse and abuse of drugs becoming the leading cause of accidental death in the U.S., Congress is looking for ways to curb the use of some prescription painkillers and insomnia/anxiety drugs. Read More

Bench Press

HIV infects CD4 "helper" T cells. But new research out of the Massachusetts Institute of Technology's Ragon Institute showed that early in the course of HIV infection, helper T cells play a greater role in controlling the disease than has been appreciated. Read More

Appointments and Advancements

• Adeona Pharmaceuticals Inc., of Ann Arbor, Mich., appointed Jeff Riley president and CEO, added C. Evan Ballantyne as chief financial officer and named Scott L. Tarriff and Nelson K. Stacks to the board. Read More

Pharma: Other News To Note

• Baxter International Inc., of Deerfield, Ill., said the European Commission granted marketing authorization of Vepacel, a pre-pandemic influenza vaccine indicated for active immunization in adults, ages 18 and older, against the H5N1 subtype of influenza A. Read More

Clinic Roundup

• Novavax Inc., of Rockville, Md., said it started enrollment in a Phase II trial of its quadrivalent seasonal influenza virus-like particle vaccine candidate. The study, being conducted under the firm's contract with the Department of Health and Human Services' Office of Biomedical Advanced Research and Development Authority, is designed to evaluate the immunogenicity and safety of three dose levels of the vaccine in healthy adults, ages 18 to 64. Read More

Stock Movers

Read More

Amicus Doubles Cash in $57M Offering; Amigal Data in 3Q12

Awaiting much-anticipated data from its pivotal Fabry disease program later this year, Amicus Therapeutics Inc. is doubling its cash balance via a $57 million public offering. Read More

Other News To Note

• Columbia Laboratories Inc., of Livingston, N.J., said it's cutting its work force by about 42 percent, from 24 employees to 14 employees, primarily in R&D and general administrative positions, to lower costs and better align operating expenses with revenues. Read More

No HAHAs for Xbiotech's Novel Antibodies, Production Method

Antibodies have come a long way. But Austin, Texas-based biopharmaceutical firm Xbiotech Inc. wants to take them further still. Read More

Start-up TremRx Thinks Best Immunity Is Only Skin Deep

Vaccines are now given as an intramuscular jab. And that delivery, Thomas Kupper told BioWorld Today, "totally bypasses the rich immunological environment of the skin.". Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 26, 2026.
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 24, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing